Yefei Rong
Overview
Explore the profile of Yefei Rong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
725
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Z, Guan Y, Gao J, Zhu L, Zeng Z, Jing Q, et al.
Oncogene
. 2025 Mar;
PMID: 40025229
Tumor cells display profound changes in the metabolism of branched-chain amino acids (BCAA). However, how these changes are regulated to facilitate tumorigenesis is not yet completely understood. Here, we identified...
2.
Lin Q, Liang L, Wang Q, Wang X, You Y, Rong Y, et al.
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672082
Background: As one of the important components of immunotherapies, mRNA vaccines have displayed promising clinical outcomes in solid tumors. Nonetheless, their efficacy remains unclear in pancreatic adenocarcinoma (PAAD). Given the...
3.
Zhao G, Jiang R, Shi Y, Gao S, Wang D, Li Z, et al.
Mol Oncol
. 2024 Apr;
18(11):2801-2813.
PMID: 38561976
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a 5-year survival rate of 7.2% in China. However, effective approaches for diagnosis of PDAC are limited. Tumor-originating genomic and...
4.
Guo X, Lou W, Xu Y, Zhuang R, Yao L, Wu J, et al.
Oncol Lett
. 2024 Mar;
27(4):161.
PMID: 38449794
Patients with advanced pancreatic cancer (PC) need a cost-effective treatment regimen. The present study was designed to compare the efficacy and safety of nab-paclitaxel plus S-1 (AS) and gemcitabine plus...
5.
Mao W, Zhang L, Rong Y, Kuang T, Wang D, Xu X, et al.
Dig Dis Sci
. 2022 Sep;
68(4):1351-1363.
PMID: 36098876
Purpose: Pancreatic cancer is characterized by a dense desmoplasia stroma, which hinders efficient drug delivery and plays a critical role in tumor progression and metastasis. MLN4924 is a first-in-class NEDD8-activating...
6.
Wang H, Mao W, Lou W, Jin D, Wu W, Wang D, et al.
J Cancer
. 2022 Apr;
13(5):1501-1511.
PMID: 35371311
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignant tumor with an extremely poor prognosis in digestive tumors. Pyrroline-5-carboxylate reductase 1 (PYCR1) plays an important role in tumor development. Therefore,...
7.
Li J, Rong Y, Mao W, Zhang L, Kuang T, Lou W
Cell Cycle
. 2021 Dec;
21(2):152-171.
PMID: 34874801
MLN4924 inhibits the proteolytic degradation of Cullin-Ring E3 ligase (CRL) substrates and exhibits antitumor activity toward various malignancies, including pancreatic cancer. MLN4924 suppresses tumor growth by altering various key regulator...
8.
Han X, Fang Y, Chen P, Xu Y, Zhou W, Rong Y, et al.
Cell Cycle
. 2021 Jan;
20(4):369-382.
PMID: 33507122
Circular RNAs (circRNAs), the new stars of endogenous non-coding RNAs, are dysregulated in various tumors including pancreatic cancer. Here, we aimed to investigate the biological functions of hsa_circ_0071036 in the...
9.
Rong Y, Gao J, Kuang T, Chen J, Li J, Huang Y, et al.
J Cell Mol Med
. 2020 Dec;
25(4):2163-2175.
PMID: 33345387
Pancreatic cancer is a highly malignant tumour of the digestive tract which is difficult to diagnose and treat. Approximately 90% of cases arise from ductal adenocarcinoma of the glandular epithelium....
10.
Han X, Chen W, Chen P, Zhou W, Rong Y, Lv Y, et al.
Pancreas
. 2020 Apr;
49(4):514-523.
PMID: 32282764
Objective: The genetic aberrations that underlie chromatin remodeling in sporadic nonfunctional pancreatic neuroendocrine tumors (NF-pNETs) remain largely unknown. Here, we investigated the dysregulation of the switch/sucrose nonfermentable (SWI/SNF) component ARID1A...